Commercial naproxen sodium tablet — Competitive Intelligence Brief

Commercial naproxen sodium tablet (Commercial naproxen sodium tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Inflammation.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Pain Management, Inflammation Small molecule

Target snapshot

Commercial naproxen sodium tablet (Commercial naproxen sodium tablet) — Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Naproxen sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Commercial naproxen sodium tablet TARGET	Commercial naproxen sodium tablet	Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Ibuprofen, Hydrocortisone	Ibuprofen, Hydrocortisone	X-pert Med GmbH	marketed	NSAID + corticosteroid combination	COX-1, COX-2, glucocorticoid receptor
Ibuprofen 2%	Ibuprofen 2%	Berlin-Chemie AG Menarini Group	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Pranoprofen eye drops	Pranoprofen eye drops	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)
Standard Dose Ibuprofen	Standard Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
optimized ibuprofen	optimized ibuprofen	OSF Healthcare System	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Ginger-ibuprofen	Ginger-ibuprofen	Ferrosan AS	marketed	NSAID with herbal adjunct	COX-1, COX-2 (ibuprofen component); multiple inflammatory pathways (ginger component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class